NCT00627627

A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer

A Phase 2, Open-Label, Single-Arm, Multicenter, Multinational Study to Evaluate the Antitumor Activity and Safety of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90(HSP90), in Patients With Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive(HER2+) Breast Cancer That Has Progressed Despite Prior Her2=Targeted Therapy

• Status: Withdrawn
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 56 (estimated)
• Sponsor: MedImmune LLC · Industry
• Sex: Female
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.

Detailed description

To evaluate the antitumor activity following treatment with IPI-504 in patients with locally advanced or metastatic HER2+ breast cancer that has progressed despite prior HER2-targeted therapy.

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	IPI-504	dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle

Timeline

• Start date: 2008-04-01
• Primary completion: 2010-02-01
• First posted: 2008-03-03
• Last updated: 2010-02-03

Locations

7 sites across 1 country: United States